Botanical species · safety record

Bupleurum falcatum

The EFSA Compendium of Botanicals holds 2 constituent measurements and 1 adverse-effect record for Bupleurum falcatum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Bupleurum falcatum L.

2Constituent measurements

1Safety records

2Cited sources

16Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 16 licensed products naming Bupleurum falcatum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Source material stated

Bupleurum chinense root
Root
Root extract
Whole plant

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Saikosaponins	Roots and other underground parts	Solvent extraction	≤ 7.85 Milligram/gram	HPLC-ELSD	Resolve DOI
Saikosaponins	Roots and other underground parts	Solvent extraction	≥ 3.81 Milligram/gram	HPLC-ELSD	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Hepatotoxicity	Urogenital: urinary bladder	—	—	House mouse (as animal)	Other	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Zhang, Feng., Chen, Li., Jin, Huanhuan., Shao, Jiangjuan., Wu, Li., Lu, Yin., Zheng, Shizhong. Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2016, vol. 41, p. 8-13. DOI
Lee, Jaehyun., Yang, Dong-Hyug., Suh, Joon Hyuk., Kim, Unyong., Eom, Han Young., Kim, Junghyun., Lee, Mi Young., Kim, Jinwoong., Han, Sang Beom. Species discrimination of Radix Bupleuri through the simultaneous determination of ten saikosaponins by high performance liquid chromatography with evaporative light scattering detection and electrospray ionization mass spectrometry. AND LIFE SCIENCES, 2011, vol. 879, no. 32, p. 3887-3895. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature